Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lobe SciencesLOBEF +5.00% Debt-to-Equity is 0.18 as of May. 2026. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Lobe Sciences ranks worse than 51.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lobe Sciences's Debt-to-Equity or its related term are showing as below:
LOBEF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.08 Med: -0.01 Max: 1.04
Current: 0.18
During the past 13 years, the highest Debt-to-Equity Ratio of Lobe Sciences was 1.04. The lowest was -2.08. And the median was -0.01.
LOBEF's Debt-to-Equity is ranked worse than 51.92% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs LOBEF: 0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lobe Sciences Debt-to-Equity Related Terms
Lobe Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lobe Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LOBEF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Lobe Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lobe Sciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lobe Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lobe Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lobe Sciences (LOBEF) has a Debt-to-Equity of 0.18 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #501 out of 965 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Lobe Sciences' Debt-to-Equity too high?
Lobe Sciences' current Debt-to-Equity is 0.18. The Biotechnology industry median Debt-to-Equity is 0.15. Lobe Sciences' value of 0.18 is 20% above this industry median. Based on the distribution chart, Lobe Sciences ranks #501 out of 965 companies in the Biotechnology industry, which is below the industry midpoint.
How does Lobe Sciences' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #501 out of 965 companies for Debt-to-Equity. This places Lobe Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Lobe Sciences' value of 0.18 is 20% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lobe Sciences's current Debt-to-Equity of 0.18 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lobe Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lobe Sciences's current Debt-to-Equity is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Debt-to-Equity of 0.18. The current Debt-to-Equity is 0.18 and 20% above the Biotechnology industry median of 0.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Debt-to-Equity is 0.18 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOBEF has been successfully added to your 
